Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

Introduction The study aimed to evaluate comparability in terms of efficacy, safety and immunogenicity of Sun’s ranibizumab biosimilar with reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD). Methods This prospective, randomised, double-blind, two-group, paral...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology and therapy Vol. 13; no. 5; pp. 1369 - 1382
Main Authors:	Ghosh, Asim K., Nikumbh, Usha S., Shukla, Chaitanya K., Laul, Rohit S., Dixit, Abhishek, Mahapatra, Santosh K., Nayak, Sameera, Shah, Urmil M., Parwal, Sandeep, Venkatapathy, Narendran, Radhakrishnan, Natasha, Kelgaonkar, Anup, Saxena, Sandeep, Mishra, Divyansh, Dave, Vivek Pravin, Khan, Perwez, Saswade, Manojkumar R., Shantilal, Malli S., Ramasamy, Kim, Sreekanta, Smitha, Rajurkar, Mandodari, Doshi, Maulik, Behera, Sapan, Patel, Piyush, Dhawan, Shilpi, Lakhwani, Lalit
Format:	Journal Article
Language:	English
Published:	Cheshire Springer Healthcare 01-05-2024 Adis, Springer Healthcare
Subjects:	Anti-VEGF Biosimilar ranibizumab Innovator ranibizumab Internal Medicine Medicine Medicine & Public Health Neovascular age-related macular degeneration Ophthalmology Original Research Biosimilar ranibizumab Innovator ranibizumab Anti-VEGF Neovascular age-related macular degeneration
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction The study aimed to evaluate comparability in terms of efficacy, safety and immunogenicity of Sun’s ranibizumab biosimilar with reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD). Methods This prospective, randomised, double-blind, two-group, parallel-arm, multicentre, phase 3 comparative study included patients with nAMD ≥ 50 years, randomised (in a 2:1 ratio) in a double-blind manner to receive 0.5 mg (0.05 mL) intravitreal injection of either Sun’s ranibizumab or reference ranibizumab in the study eye every 4 weeks until week 16 (total of four doses). Results Primary endpoint results demonstrated equivalence in the proportion of patients who lost fewer than 15 letters from baseline best-corrected visual acuity (BCVA) to the end of week 16 (99% of patients in Sun’s ranibizumab and 100% in reference ranibizumab; p > 0.9999), with the proportional difference (90% confidence interval) at −1% (−2.51, +0.61) lying within a pre-specified equivalence margin. Visual acuity improved by 15 or more letters in 43% of Sun’s ranibizumab group and 37% of the reference ranibizumab group ( p = 0.4267). The mean increase in BCVA was 15.7 letters in Sun’s ranibizumab group and 14.6 letters in the reference ranibizumab group ( p < 0.001 within both groups and p = 0.5275 between groups). The mean change in central macular thickness was comparable between groups ( p = 0.7946). Anti-ranibizumab antibodies were found in one patient of the reference ranibizumab group, while neutralising antibodies were not found in any patients. Both products were well tolerated. Conclusion Sun’s ranibizumab biosimilar is found to be therapeutically equivalent to reference ranibizumab in patients with nAMD. There were no additional safety or immunogenicity concerns. Trial Registration CTRI/2020/09/027629, registered on 07 September 2020.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2193-8245 2193-6528
DOI:	10.1007/s40123-024-00883-5